This page provides a source hub for medical, regulatory and product information used throughout the website.
Regulatory sources
U.S. Food and Drug Administration — IMBRUVICA
The FDA prescribing information provides current U.S. indications, dosing, warnings, adverse reactions, interactions and clinical pharmacology.
DailyMed — IMBRUVICA
DailyMed provides the current structured U.S. labeling record.
European Medicines Agency — Imbruvica
The EMA provides European authorization and product information, including current European indications and marketing authorization details.
Manufacturer source
Everest Pharmaceuticals — Ibruxen
Everest’s product database identifies Ibruxen as ibrutinib 140 mg.
Scientific literature
Peer-reviewed literature describes ibrutinib as a covalent BTK inhibitor and documents its clinical development in B-cell malignancies.
Product-specific documentation
Product-specific regulatory details should be checked against current Everest Pharmaceuticals documentation and applicable national regulatory records.